Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.

[1]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[2]  E. Rosenberg,et al.  Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. , 2006, Blood.

[3]  Bernard Verrier,et al.  Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. , 2006, Blood.

[4]  C. Rouzioux,et al.  Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals , 2006, AIDS.

[5]  L. Dorrell Therapeutic immunization strategies for the control of HIV-1 , 2005, Expert review of vaccines.

[6]  C. Heirman,et al.  Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy , 2005, The journal of gene medicine.

[7]  Felipe García,et al.  Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. , 2005, The Journal of infectious diseases.

[8]  F. Brasseur,et al.  Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.

[9]  A. Palucka,et al.  Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.

[10]  A. Órfão,et al.  Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection , 2005, AIDS.

[11]  Wei Lu,et al.  Therapeutic dendritic-cell vaccine for chronic HIV-1 infection , 2004, Nature Medicine.

[12]  R. Koup,et al.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know , 2004, Nature Medicine.

[13]  Todd M. Allen,et al.  HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α , 2004 .

[14]  E. Gilboa,et al.  Cancer immunotherapy with mRNA‐transfected dendritic cells , 2004, Immunological reviews.

[15]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[16]  L. B. de Arruda,et al.  DNA vaccine encoding human immunodeficiency virus‐1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal‐associated membrane protein, elicits enhanced long‐term memory response , 2004, Immunology.

[17]  G. Pantaleo,et al.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. , 2004, Blood.

[18]  C. Heirman,et al.  Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells , 2003, Cancer Gene Therapy.

[19]  B. Walker,et al.  Therapeutic vaccines against HIV need international partnerships , 2003, Nature Reviews Immunology.

[20]  O. Yang Will we be able to 'spot' an effective HIV-1 vaccine? , 2003, Trends in immunology.

[21]  M. Baalen,et al.  Impact of antigen expression kinetics on the effectiveness of HIV‐specific cytotoxic T lymphocytes , 2002, European journal of immunology.

[22]  J. Tartaglia,et al.  A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. , 2002, Vaccine.

[23]  A. Osterhaus,et al.  Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. , 2002, Vaccine.

[24]  C. Broeckhoven,et al.  mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation , 2002, Leukemia.

[25]  Kris Thielemans,et al.  Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.

[26]  D. Richman,et al.  Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression , 2002, AIDS.

[27]  M. Robert-Guroff,et al.  Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. , 2001, Immunology letters.

[28]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[29]  J. Lieberman,et al.  Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. , 2000, Blood.

[30]  V. Calvez,et al.  Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 , 2000, The Journal of Immunology.

[31]  Douglas D. Richman,et al.  HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.

[32]  H. Kessler,et al.  Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. , 1999, Journal of immunology.

[33]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[34]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[35]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[36]  F. Miedema,et al.  Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. , 1997, The Journal of general virology.

[37]  Brian Seed,et al.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.

[38]  M. Malim,et al.  Mutational definition of the human immunodeficiency virus type 1 Rev activation domain , 1991, Journal of virology.

[39]  C. Debouck,et al.  Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat , 1990, The Journal of cell biology.

[40]  M. Malim,et al.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein , 1989, Journal of virology.

[41]  S. Josephs,et al.  Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  V. Ovod,et al.  Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines , 2005, Archives of Virology.

[43]  J. Lieberman,et al.  Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. , 2003, Blood.

[44]  C. Kuiken,et al.  HIV sequence databases. , 2003, AIDS reviews.

[45]  P. Easterbrook,et al.  Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. , 2002, Journal of immunology.